12.90
price down icon5.49%   -0.75
after-market アフターアワーズ: 12.80 -0.10 -0.78%
loading
前日終値:
$13.65
開ける:
$13.65
24時間の取引高:
2.84M
Relative Volume:
1.13
時価総額:
$1.15B
収益:
$217.42M
当期純損益:
$-243.25M
株価収益率:
-4.6151
EPS:
-2.7952
ネットキャッシュフロー:
$-278.35M
1週間 パフォーマンス:
-24.07%
1か月 パフォーマンス:
-25.35%
6か月 パフォーマンス:
-45.82%
1年 パフォーマンス:
-14.29%
1日の値動き範囲:
Value
$12.81
$13.65
1週間の範囲:
Value
$12.81
$16.95
52週間の値動き範囲:
Value
$12.81
$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
名前
Syndax Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
781-419-1400
Name
住所
730 THIRD AVENUE, NEW YORK, MA
Name
職員
298
Name
Twitter
@syndax
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
SNDX's Discussions on Twitter

Compare SNDX vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SNDX icon
SNDX
Syndax Pharmaceuticals Inc
12.90 1.15B 217.42M -243.25M -278.35M -2.7952
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-16 再開されました H.C. Wainwright Buy
2025-09-10 再開されました Stifel Buy
2025-09-04 再開されました Guggenheim Buy
2025-08-05 繰り返されました BTIG Research Buy
2025-07-10 開始されました Goldman Buy
2024-10-24 開始されました UBS Buy
2024-06-28 開始されました Jefferies Buy
2024-01-31 ダウングレード Scotiabank Sector Outperform → Sector Perform
2023-12-22 開始されました Mizuho Buy
2023-10-25 開始されました BofA Securities Buy
2023-10-11 開始されました Goldman Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-11 開始されました Guggenheim Buy
2023-04-17 再開されました BTIG Research Buy
2023-01-31 開始されました Stifel Buy
2023-01-03 開始されました JP Morgan Overweight
2022-07-28 再開されました B. Riley Securities Buy
2022-04-11 開始されました H.C. Wainwright Buy
2022-02-15 開始されました Goldman Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-25 開始されました Citigroup Buy
2021-02-18 開始されました B. Riley Securities Buy
2020-12-03 開始されました Stifel Buy
2020-05-22 アップグレード Citigroup Neutral → Buy
2020-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2020-05-18 ダウングレード Citigroup Buy → Neutral
2020-05-11 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-13 繰り返されました H.C. Wainwright Buy
2019-03-08 繰り返されました H.C. Wainwright Buy
2019-01-04 開始されました Robert W. Baird Outperform
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-03-16 開始されました FBR & Co. Outperform
2017-03-02 開始されました Instinet Buy
2016-10-07 開始されました Guggenheim Buy
2016-03-28 開始されました Citigroup Buy
2016-03-28 開始されました JMP Securities Mkt Outperform
2016-03-28 開始されました Morgan Stanley Overweight
すべてを表示

Syndax Pharmaceuticals Inc (SNDX) 最新ニュース

pulisher
Oct 15, 2026

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List - GlobeNewswire

Oct 15, 2026
pulisher
Oct 14, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire

Oct 14, 2026
pulisher
Oct 14, 2026

Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street

Oct 14, 2026
pulisher
Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView

Oct 14, 2026
pulisher
Oct 13, 2026

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals Suffers Pipeline BlowSyndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside - TradingView

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownHere's What Happened - MarketBeat

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. - Barron's

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright - MarketBeat

Oct 13, 2026
pulisher
Oct 13, 2026

BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals (NasdaqGS:SNDX) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals (SNDX) Stock Forecast and Price Target 2026 - MarketBeat

Oct 13, 2026
pulisher
Oct 13, 2026

Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance

Oct 13, 2026
pulisher
Oct 12, 2026

Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss - Mugglehead Investment Magazine

Oct 12, 2026
pulisher
Oct 12, 2026

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus

Oct 12, 2026
pulisher
Oct 12, 2026

Syndax Pharmaceuticals' Axatilimab Trial in Pulmonary Fibrosis Misses Primary Endpoint - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Syndax says mid-stage trial of lung disease treatment fails main goal, ends development - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Syndax Pharmaceuticals stock tumbles on failed IPF trial - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire

Oct 12, 2026
pulisher
Oct 10, 2026

Possible Bearish Signals With Syndax Pharmaceuticals Insiders Disposing Stock - Moomoo

Oct 10, 2026
pulisher
Oct 09, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat

Oct 09, 2026
pulisher
Oct 02, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026
pulisher
Oct 02, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving AverageHere's What Happened - MarketBeat

Oct 02, 2026
pulisher
Sep 30, 2026

Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3 - TradingView

Sep 30, 2026
pulisher
Sep 28, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 28, 2026
pulisher
Sep 28, 2026

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX) - Seeking Alpha

Sep 28, 2026
pulisher
Sep 25, 2026

Syndax Pharmaceuticals poised for growth with p... - Pluang

Sep 25, 2026
pulisher
Sep 25, 2026

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha

Sep 25, 2026
pulisher
Sep 25, 2026

Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors - BioWorld News

Sep 25, 2026
pulisher
Sep 24, 2026

Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media

Sep 24, 2026
pulisher
Sep 23, 2026

How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 23, 2026
pulisher
Sep 23, 2026

How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 23, 2026
pulisher
Sep 22, 2026

H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Sep 22, 2026
pulisher
Sep 19, 2026

Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com

Sep 19, 2026
pulisher
Sep 18, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 13, 2026

WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 13, 2026
pulisher
Sep 13, 2026

How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 13, 2026
pulisher
Sep 12, 2026

Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com

Sep 12, 2026
pulisher
Sep 11, 2026

Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 11, 2026
pulisher
Sep 10, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat

Sep 10, 2026
pulisher
Sep 07, 2026

Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 07, 2026
pulisher
Sep 05, 2026

Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com

Sep 04, 2026
pulisher
Sep 04, 2026

Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026

Syndax Pharmaceuticals Inc (SNDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Syndax Pharmaceuticals Inc (SNDX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Metzger Michael A
Chief Executive Officer
Jul 08 '26
Sale
24.24
32,375
784,776
484,843
MICHAEL METZGER
Director
Jul 08 '26
Proposed Sale
23.24
32,375
752,395
0
Botwood Nicholas A.J.
Officer
Jun 12 '26
Proposed Sale
18.14
31,235
566,693
0
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 12 '26
Sale
18.14
31,235
566,603
60,885
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 12 '26
Option Exercise
13.82
31,235
431,668
92,120
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 11 '26
Sale
18.00
34,280
617,040
60,885
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 11 '26
Option Exercise
13.82
22,515
311,157
95,165
Botwood Nicholas A.J.
Officer
Jun 11 '26
Proposed Sale
17.78
34,280
609,435
0
Goldan Keith A.
Chief Financial Officer
Jun 01 '26
Sale
18.99
1,177
22,351
139,252
Metzger Michael A
Chief Executive Officer
Jun 01 '26
Sale
18.99
6,847
130,025
484,843
$18.44
price down icon 1.60%
$12.29
price down icon 6.61%
$16.20
price down icon 13.78%
IAM IAM
$23.81
price up icon 0.00%
$3.62
price down icon 2.95%
$36.74
price up icon 0.14%
大文字化:     |  ボリューム (24 時間):